# APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma

> **NCT03287804** · PHASE1,PHASE2 · TERMINATED · sponsor: **Autolus Limited** · enrollment: 12 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** AUTO2

## Key facts

- **NCT ID:** NCT03287804
- **Lead sponsor:** Autolus Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-05-05
- **Primary completion:** 2019-09-05
- **Final completion:** 2019-09-05
- **Target enrollment:** 12 (ACTUAL)
- **Why stopped:** Preliminary efficacy seen to date following treatment with AUTO2 has been determined not sufficient to warrant further development
- **Last updated:** 2020-10-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03287804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03287804, "APRIL CAR T Cells (AUTO2) Targeting BCMA and TACI for the Treatment of Multiple Myeloma". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03287804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*